AML: making residual disease more measurable
Open Access
- 4 August 2022
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 140 (5) , 415-417
Abstract
In this issue of Blood, Li et al1 show that detection of leukemic stem cells (LSCs) may predict relapse and overall survival (OS) after allogeneic hematopoieticKeywords
This publication has 10 references indexed in Scilit:
- An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective studyBlood, 2022
- CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AMLLeukemia, 2022
- 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyBlood, 2021
- Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and AzacitidineJournal of Clinical Oncology, 2021
- CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemiaLeukemia & Lymphoma, 2021
- Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre settingBritish Journal of Haematology, 2020
- CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemiaLeukemia, 2018
- Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem CellsCancer Cell, 2018
- Tracing the origins of relapse in acute myeloid leukaemia to stem cellsNature, 2017
- A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemiaLeukemia, 2015